SCHEMBL12420949

SCHEMBL12420949

CCC(c1ccccc1)n1cnc2ccc(NC(=O)c3cc(OC)ccc3Br)cc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.44
RAB9A P51151 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
ITGB1 P05556 1/20 0.41
ITGA4 P13612 1/20 0.41
CASP3 P42574 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
CA9 Q16790 4/20 0.40
HPGD P15428 2/20 0.40
AVPR2 P30518 1/20 0.40
GPR27 Q9NS67 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
F2RL1 P55085 1/20 0.40
AKR1C3 P42330 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2297563 0.92 NPC1 (0.43) NPC1RAB9AMEN1KMT2ARXFP1
SCHEMBL5306613 0.86 PTGFR (0.39) NPC1RAB9AMEN1KMT2ARXFP1
SCHEMBL2358248 0.85 SMN1; SMN2 (0.45) NPC1RAB9AMEN1KMT2ARXFP1
SCHEMBL5306619 0.85 TRPV1 (0.38) NPC1RAB9AMEN1KMT2ARXFP1
SCHEMBL2298688 0.79 NPC1 (0.48) NPC1RAB9AMEN1KMT2AMAPK1
SCHEMBL2299134 0.79 NPC1 (0.49) NPC1RAB9AKMT2AHPGDSMN1; SMN2
SCHEMBL12421965 0.76 KMT2A (0.46) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL2297594 0.76 PRNP (0.41) MEN1KMT2ASMN1; SMN2
SCHEMBL5304516 0.76 NPC1 (0.43) NPC1RAB9ASMN1; SMN2
SCHEMBL2297445 0.75 ALDH1A1 (0.47) NPC1RAB9AMEN1KMT2ARXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8003806-B2 Integrin antagonists useful as anticancer agents OSI Pharmaceuticals, LLC (US) 2011-08-23 US disclosed